Ribavirin elaidate

Drug Profile

Ribavirin elaidate

Alternative Names: CP-4033; Ribavirin-5'-elaidic acid ester ; UNII-4LU13X0I13

Latest Information Update: 17 Nov 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Clavis Pharma
  • Developer Translational Therapeutics
  • Class Antivirals; Furans; Ribonucleosides; Small molecules; Triazoles
  • Mechanism of Action Eukaryotic initiation factor 4E inhibitors; Oncogene protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer

Highest Development Phases

  • No development reported Thyroid cancer

Most Recent Events

  • 17 Nov 2013 No development reported - Preclinical for Thyroid cancer in USA (unspecified route)
  • 09 Oct 2013 Clavis Pharma is now called Aqualis
  • 02 Sep 2011 Ribavirin elaidate receives Orphan Drug status for Thyroid cancer in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top